Pharmacokinetics of Panaxynol in Mice

Area of Science:

• Pharmacology
• Drug Metabolism
• Toxicology

Background:

• Panaxynol (PA) is a compound with potential therapeutic applications.
• Understanding its pharmacokinetic profile is crucial for pre-clinical development.
• Assessing toxicity is essential for evaluating safety and dosage.

Purpose of the Study:

• To determine the pharmacokinetic parameters of Panaxynol (PA) in pre-clinical animal models.
• To evaluate the potential dosage and safety of PA.
• To investigate PA's metabolic behavior in vitro and in vivo.

Main Methods:

• In vitro studies utilized mouse and human liver microsomes with liquid chromatography-tandem mass spectrometry (LC-MS/MS).
• In vivo studies involved intravenous (IV) and oral (PO) administration of PA to CD-1 mice.
• Pharmacokinetic parameters were calculated using non-compartmental analysis and LC-MS/MS concentration measurements.

Main Results:

• In vitro, PA half-life was 21.4 min (mouse) and 48.1 min (human).
• In vivo, PA half-life was 1.5 hr (IV) and 5.9 hr (PO) with 50.4% bioavailability.
• No toxicity was observed up to 300 mg/kg PO, with highest concentrations in colon tissue.

Conclusions:

• Panaxynol (PA) demonstrates favorable pharmacokinetic properties in mice.
• The compound exhibits moderate bioavailability and a good safety profile.
• These findings support the potential use of PA in pre-clinical settings.